National Cancer Institute Regina Elena

Rome 00144

0 studies enrolling now · 1 studies all time

What they study most

HER2+ Metastatic Breast Cancer (MBC)

Studies at this site

• A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting — Completed